A specific methylation signature recently reported distinguishes between GBM with and without SVZ involvement in isocitrate dehydrogenase (IDH) wild type (IDHwt) GBM, an approach that has the potential to improve patient risk stratification and to individualize future patient care [12, 13]. The gene discussed is IDH3A; the disease is glioblastoma.